Can Chronic Lymphocytic Leukemia Turn Into Lymphoma?

Chronic lymphocytic leukemia can, in a small but significant fraction of patients, transform into an aggressive lymphoma. This shift is called Richter transformation, and it occurs in roughly 2 to 10 percent of people with CLL over the course of their disease. The transformation most often produces diffuse large B-cell lymphoma, a fast-growing cancer that behaves very differently from the typically slow-moving CLL it emerged from. Understanding when and why this happens matters because Richter transformation dramatically changes prognosis and demands a completely different treatment approach.

What Richter Transformation Actually Is

CLL is usually a low-grade, slow-growing blood cancer. Many people live with it for years, sometimes decades, before needing treatment. Richter transformation is a sudden change in the biology and behavior of that cancer: the relatively indolent CLL cells give way to an aggressive lymphoma. The overall incidence runs at about half a percent to one percent per year of follow-up, meaning the risk accumulates the longer someone lives with CLL.¹ The condition was first described in 1928 by Maurice Richter, and the name has stuck ever since.

The transformation can happen in people who have never been treated for CLL, though it is more common in those who have received therapy.¹ Survival after transformation is generally measured in months to a couple of years, a stark contrast to the often-favorable outlook of CLL itself.²

The Types of Lymphoma That Can Emerge

The overwhelming majority of Richter transformations produce diffuse large B-cell lymphoma (DLBCL). About 5 percent of CLL patients who undergo transformation develop this aggressive subtype.³ Far less frequently, the transformation takes the form of classic Hodgkin lymphoma, sometimes called the Hodgkin variant of Richter transformation. The two have different treatment strategies and different prognoses. The Hodgkin variant, while still serious, tends to have somewhat better outcomes than the DLBCL form.

There are also rarer presentations. A 2021 workshop organized by hematopathology societies examined dozens of CLL progression cases and noted that the spectrum of transformation is genuinely diverse, including unusual morphologies that can challenge even experienced pathologists.⁴ These atypical cases underscore why a tissue biopsy, not just imaging, is essential whenever transformation is suspected.

Where the Aggressive Lymphoma Comes From

One of the most important questions in Richter transformation is whether the new lymphoma is actually the original CLL that evolved, or a completely unrelated new cancer that happened to arise in the same patient. The answer matters for prognosis: when the lymphoma is clonally related to the underlying CLL, meaning it descended from the same original cancerous B cell, outcomes tend to be worse than when it is a clonally unrelated second cancer.

The standard way to test this involves comparing the genetic fingerprint of the antibody genes in both the CLL cells and the lymphoma cells. If both share the same unique rearrangement in their immunoglobulin heavy chain gene, they almost certainly came from the same clone.⁵ Landmark work in the early 1990s was the first to conclusively establish this clonal relationship, showing through detailed gene-sequencing that the aggressive lymphoma cells in some patients are mutant descendants of the original CLL cells.⁶

In clonally related cases, the CLL essentially acquires new genetic damage that pushes it into a much more aggressive growth pattern. Researchers have mapped this progression as a model of cancer evolution: from the earliest stage of a condition called monoclonal B-cell lymphocytosis, through CLL, and in some patients all the way to Richter transformation, each step driven by accumulating genetic changes.⁷ A substantial majority of DLBCL-type Richter transformations, around 80 percent in some series, turn out to be clonally related to the patient’s CLL.⁸

Genetic Changes That Drive Transformation

Several genetic alterations appear repeatedly in Richter transformation and seem to be the molecular switches that push CLL toward aggressive lymphoma. The most common changes, found in 40 to 60 percent of cases, involve a rearrangement or extra copies of the MYC gene (a powerful growth driver), loss of the TP53 tumor-suppressor gene, loss of the CDKN2A gene (another tumor suppressor), rearrangement of the immunoglobulin heavy chain gene, and deletion of a region on chromosome 13.⁹ TP53 and MYC are two of the most studied genes in cancer biology generally, and their disruption in Richter transformation fits a broader pattern: when these safeguards fail, cells grow unchecked.

NOTCH1 mutations also show up in a meaningful share of transformed cases. In a large study of CLL patients on ibrutinib who developed Richter transformation, about a quarter carried mutated NOTCH1.⁸ NOTCH1 is part of a cell-signaling pathway that, when stuck in the “on” position, helps cancer cells survive and multiply.

Who Is at Higher Risk

Not everyone with CLL faces the same odds of transformation. Several factors at the time of CLL diagnosis flag a higher risk. Patients whose CLL cells carry an unmutated version of the immunoglobulin heavy-chain variable region gene have a higher transformation rate, as do those with TP53 deletions or mutations. Interestingly, younger age (under 70) is also an independent risk factor, possibly because younger patients’ cancers tend to have more aggressive biology.⁸

Other markers linked to increased risk include expression of CD38 on CLL cells, lymph nodes larger than 3 centimeters, short telomeres in CLL cells, and the use of specific immunoglobulin gene segments, particularly IGHV4-39. Certain inherited genetic variations at the CD38 gene locus also appear to play a role.¹⁰ Prior treatment for CLL is another risk factor, though in at least one large analysis it fell just short of independent statistical significance after adjusting for other variables.⁸

In practice, the cumulative risk varies considerably depending on how many of these factors a patient carries. In one study of nearly a thousand CLL patients on ibrutinib, the seven-year transformation rate ranged from about 4 percent in low-risk patients to over 22 percent in those with multiple risk factors.⁸ That five-fold spread underscores why individual risk assessment matters.

Warning Signs to Watch For

CLL can be stable for years, so the challenge for patients and their care teams is recognizing when something has changed. The classic red flags for Richter transformation include a rapid clinical decline with fever that cannot be explained by an infection, a sudden and noticeable enlargement of one or more lymph nodes, and a spike in a blood marker called lactate dehydrogenase (LDH).¹¹ Worsening fatigue, drenching night sweats, unintended weight loss, and new or worsening cytopenias (low blood counts) can also signal transformation.

The difficulty is that some of these symptoms overlap with CLL progression that has not crossed into true transformation. CLL itself can cause growing lymph nodes, fatigue, and night sweats. The speed and severity of change is what distinguishes Richter transformation: a lymph node that grew modestly over six months is different from one that doubled in two weeks. Any abrupt worsening of symptoms in a CLL patient should prompt a conversation with their hematologist about whether transformation testing is needed.

How Transformation Is Diagnosed

PET-CT scanning has become a standard first step when Richter transformation is suspected. This imaging technique highlights areas where cells are metabolically very active, which aggressive lymphoma cells tend to be. A high SUVmax value (a measure of metabolic activity on PET) in a lymph node raises suspicion. An international consensus statement recommends using a threshold of SUVmax 5 or higher to identify patients at risk: at that level, sensitivity for detecting transformation runs around 88 to 96 percent, though the positive predictive value is lower, only 38 to 51 percent. When SUVmax falls below 5, the chance of finding true transformation on biopsy is extremely low, just 3 to 8 percent.¹²

That said, PET-CT alone is not sufficient. There is overlap in metabolic activity between aggressive CLL and true Richter transformation, and this overlap can be even more pronounced in patients who have been on targeted therapies like kinase inhibitors. One analysis of patients who progressed after kinase inhibitor therapy found that a SUVmax threshold of 10 did not reliably distinguish transformation from simple CLL progression in that setting.¹³ For this reason, a tissue biopsy of the most metabolically active accessible lymph node remains mandatory for a definitive diagnosis.¹²

Treatment and Prognosis

Treating Richter transformation is one of the hardest problems in hematologic oncology. The standard first-line approach has traditionally been R-CHOP, a combination chemotherapy regimen widely used for DLBCL in the general population. In Richter transformation specifically, results have been disappointing. One prospective trial found that about two-thirds of patients responded initially, but progression-free survival was only 10 months and overall survival 21 months. Nearly half of patients had to stop treatment early, mostly because of toxicity, with serious blood-count problems in over 90 percent and severe infections in about 28 percent.¹⁴ R-CHOP may still serve a role as a bridge to get a patient into remission before a stem cell transplant, but by itself it is not a long-term solution for most patients.

Allogeneic stem cell transplant (using a donor’s cells) remains the only proven potentially curative approach, but it carries serious risks. In a retrospective study of 66 transplanted Richter transformation patients, three-year overall survival was about 39 percent and three-year progression-free survival about 29 percent. Patients who entered transplant in complete remission did significantly better, with three-year progression-free survival of 39 percent compared to 21 percent for those not in remission. However, treatment-related death (non-relapse mortality) was high at 38 percent over three years, and more than half of patients developed chronic graft-versus-host disease.¹⁵ These numbers reflect the fundamental tension in this disease: the treatment aggressive enough to eliminate the cancer is also aggressive enough to cause serious harm.

Newer Therapies Offering Hope

The treatment landscape is shifting as newer targeted and immune-based therapies enter clinical use. CAR T-cell therapy, which engineers a patient’s own immune cells to attack cancer, has shown encouraging early results. A European multicenter analysis of 54 patients with Richter transformation treated with anti-CD19 CAR T-cells reported an overall response rate of 65 percent, with about half achieving complete remission. Median progression-free survival was 8 months, and median overall survival reached about 14 months, with manageable side effects.¹⁶ Those numbers may not sound dramatic, but for a disease where median survival after chemotherapy is often measured in single-digit months, they represent meaningful progress.

Other emerging approaches include T-cell-engaging bispecific antibodies (drugs that physically link immune T cells to tumor cells), noncovalent BTK inhibitors, and immune checkpoint inhibitors.¹⁷ Early research on checkpoint inhibitors is interesting in part because of the unusual immune environment in Richter transformation. Studies of the tumor microenvironment have found that many cases of Richter transformation show enrichment of exhausted but still cytotoxic T cells, a pattern that may make them responsive to therapies designed to re-activate those tired immune cells.¹⁸ Larger prospective trials are still needed to confirm which of these strategies works best, and researchers are particularly interested in combination approaches.¹⁹

Does Modern CLL Treatment Affect Transformation Risk

The widespread adoption of BTK inhibitors like ibrutinib has transformed how CLL itself is managed, so a natural question is whether these drugs increase, decrease, or have no effect on the risk of Richter transformation. The answer is still being worked out, but the data so far suggest that transformation remains a real concern even on these newer agents. In a study of 976 CLL patients treated with ibrutinib, 8.5 percent developed DLBCL-type Richter transformation, with a cumulative rate of about 15.6 percent at seven years.⁸ The risk factors were the same ones seen in the broader CLL population: younger age, TP53 abnormalities, and prior treatment.

What remains unclear is whether ibrutinib itself contributes to the risk of transformation or whether patients on ibrutinib simply have higher-risk CLL to begin with, since ibrutinib is often used in patients with aggressive disease features. The timing is also worth noting: many transformations occur within the first one to two years of ibrutinib therapy, suggesting the transformation may have already been developing before treatment started. Regardless, the takeaway for patients is that being on a targeted therapy does not eliminate the need for vigilance about transformation.

When CLL Progresses Without Transforming

Not every deterioration in CLL means Richter transformation has occurred. CLL can also accelerate, meaning it grows faster and causes worse symptoms while still remaining CLL histologically. This is sometimes called accelerated CLL or CLL with increased proliferation centers. The distinction is important because accelerated CLL, while more concerning than stable disease, has a different prognosis and treatment approach than full-blown Richter transformation.

The diagnostic criteria for accelerated CLL are well established for lymph-node biopsies, but recognizing acceleration in other tissues can be tricky.⁴ Additionally, CLL patients face a modestly increased risk of developing entirely unrelated second cancers, including lymphomas that have no connection to their CLL. When a CLL patient develops a new lymphoma, determining whether it is a true Richter transformation from the original CLL clone, an unrelated new cancer, or an unusual variant requires careful pathological evaluation and often molecular testing of clonal relatedness. Getting this distinction right shapes everything from the prognosis the patient is given to the treatment plan that follows.

The Immune Microenvironment in Richter Transformation

Researchers are increasingly interested in what happens to the immune system around the tumor when CLL shifts to aggressive lymphoma. The tumor microenvironment in Richter transformation appears to be immunologically “hotter” than in standard CLL, with more immune cells present and more inflammatory signaling. Specifically, single-cell studies have found enrichment of CD8-positive effector T cells that show signs of exhaustion alongside CD4-positive T cells with cytotoxic capacity, as well as pro-inflammatory macrophages producing signaling molecules like CXCL9 and CXCL10.¹⁸

This is relevant beyond basic science because it helps explain why immune checkpoint blockade, which works by releasing the brakes on exhausted T cells, might be effective in Richter transformation even though it has limited activity in CLL alone. The pre-existing cytotoxic capacity of the T cells in the tumor microenvironment essentially means there are immune cells that want to kill the cancer but are being held back. Checkpoint inhibitors aim to remove that restraint. This line of research could eventually help clinicians predict which Richter transformation patients are most likely to benefit from immunotherapy based on the immune profile of their tumors, moving toward a more personalized treatment approach for a disease that desperately needs one.